Journals / Acıbadem Üniversitesi Sağlık Bilimleri Dergisi / 2019 / Sayı: 2

Side Effects and Management of Immunotherapy In Cancer

Kanserde İmmünoterapi Yan Etkileri ve Yönetimi

Pages
142–147
Publication Date
2019-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Increasing the experience with these drugs will enable more effective treatment algorithms to be developed and a better understanding of the side effect profile

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In oncology, the activity of monoclonal antibodies which known as immune checkpoint inhibitors is better understood every day.
📊
Key Findings & Data:These drugs are efficaciousby inhibiting the inhibitory mechanisms in the immune system and their side effects can be defined as autoimmune events that caused by excessive immune response..
💡
Conclusion & Impact:Increasing the experience with these drugs will enable more effective treatment algorithms to be developed and a better understanding of the side effect profile
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Cancer · immunotherapy · side effect

Abstract

In oncology, the activity of monoclonal antibodies which known as immune checkpoint inhibitors is better understood every day. These drugs are efficaciousby inhibiting the inhibitory mechanisms in the immune system and their side effects can be defined as autoimmune events that caused by excessive immune response.. Immunerelated side effects are not very common and can usually be treated with steroids and dose modifications. Immunosuppressive treatments are used in resistant cases. Increasing the experience with these drugs will enable more effective treatment algorithms to be developed and a better understanding of the side effect profile

Özet

İmmün kontrol noktası inhibitörleri olarak bilinen monoklonal antikorların onkoloji alanındaki etkinlikleri hergeçen gün daha iyi anlaşılmaktadır. Bu ilaçlar immün sistem üzerindeki inhibitör mekanizmaların engellenmesi yoluyla etkinlik göstermektedirler ve yan etkileri de aşırı immün yanıt sonucu ortaya çıkan otoimmün olaylar olarak tanımlanabilir. İmmün aracılı yan etkiler çok sık olmamakla beraber ilacın kesilmesi ve streoid kullanımı ile genellikle gerilemektedir. Dirençli vakalarda immünsüpresif tedaviler kullanılmaktadır.Bu ilaçlar ile olan deneyimlerin artması daha etkili tedavi algoritmaları geliştirilebilmesine ve yan etki profilinin daha iyi anlaşılabilmesine olanak sağlayacaktır

🔖

Cite This Article

ÇALIKUŞU, Z. (2019). Side Effects and Management of Immunotherapy In Cancer. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, Sayı: 2, 142–147. https://ajindex.com/articles/162859

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti- PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375-91. (CrossRef) Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016; 27:559-74. (CrossRef) Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol 2016;35:785-92. (CrossRef) Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23. (CrossRef) h t t p: / / w w w. a c c e s s d a t a. f d a. g o v / d r u g s a t f d a _ d o c s / label/2017/761049s000lbl.pdf (Accessed on March 26, 2019).
  2. Zarbo A, Belum VR, Sibaud V, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 2017;176:1649-52. (CrossRef) Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-7. (CrossRef) Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71:161-9. (CrossRef) Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 2013; 119:1675-82. (CrossRef) Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64. (CrossRef) Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013; 31:616-22.
  3. Bernardo SG, Moskalenko M, Pan M, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 2013; 23:47-54. (CrossRef) http://packageinserts.bms.com/pi/pi_opdivo.pdf (Accessed on March 26, 2019).
  4. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44. (CrossRef) Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of Programmed Cell Dea